作为一名乳腺医学肿瘤学家，我的使命和目标一直是减轻乳腺癌. After 20 years in academia and clinical practice, 我目前担任的职位是乳腺癌和乳腺癌研究战略全球主管，这使我能够开拓和扩展新的全球转化研究和创新临床试验开发，从而加速澳门在线赌城娱乐卓越关键领域的既定和新型药物的批准, tumour resistance/ targeted therapies, DNA damage response, antibody-drug conjugates, and immuno-oncology.

我的总体愿景是促进乳腺癌治疗的范式转换和实践改变，以降低死亡率, morbidity, and health disparities, 以及解决乳腺癌医学领域的关键知识空白. 

Before joining AstraZeneca, 我在范德比尔特大学医学中心担任医学教授和英格拉姆癌症研究教授18年, 在我的职业生涯中，我成功地指导过研究员和初级教员. 作为一名乳腺癌医学肿瘤学家，我为成千上万的患者提供了最先进的护理. I have extensive experience with novel therapeutics in phase I, II and III clinical trials, 曾担任超过90项临床试验的首席研究员，从I期到III期. 我在乳腺癌的转化研究主要集中在确定治疗耐药的靶向途径和机制, 得到了NCI的认可和资助(乳腺癌中的K23和孢子), SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation, and published in more than 135 peer-reviewed journals. I have chaired, 美国许多国家和国际卫生服务癌症领导委员会的共同主席或成员, such as ECOG-ACRIN Breast Core Committee, 国家综合癌症网络(NCCN)乳腺癌专家小组, Translational Breast Cancer Research Consortium (TBCRC) amongst many others.

从床到床的研究使澳门第一赌城在线娱乐改变了乳腺癌的治疗模式和实践, making treatments more effective and patient-centred. 我对澳门第一赌城在线娱乐正在进行的有助于降低死亡率的研究感到兴奋, morbidity and health disparities for breast cancer patients

Ingrid A. Mayer Global Clinical Head for Breast Cancer and Breast Cancer Strategy

Honor

Komen Scholar (2018-2022)

Shortlisted

Top Doctors; Castle Connolly (2013-2021)

Award

VICC Star Award for Leadership in Cancer Clinical Investigation (2011-2021)

Ingrid Mayer，全球临床乳腺癌和乳腺癌策略，研究 & Development, at AstraZeneca.

CURRENT ROLE

范德比尔特大学医学中心医学教授和癌症研究英格拉姆教授/乳腺癌和乳腺癌研究策略全球负责人

2021

范德比尔特大学医学中心血液学/肿瘤学科主任

2021

Membership Committee Member; European Society of Medical Oncology

2014 – 2021

乳腺癌项目临床负责人NCI乳腺癌研究优秀专业项目(SPORE)临床负责人, Vanderbilt-Ingram Cancer Center

 Featured publications

γ分泌酶抑制剂RO4929097联合依西美坦治疗ER +转移性乳腺癌(MBC)的Ib期剂量递增试验

Means-Powell JA, Mayer IA, Ismail-Khan R, Del Valle L, Tonetti D, Abramson VG, Sanders MS, Lush RM, Sorrentino C, Majumder S, Miele L. γ分泌酶抑制剂RO4929097联合依西美坦治疗ER +转移性乳腺癌(MBC)的Ib期剂量递增试验. Clin Breast Cancer. 2021 Oct 28:S1526-8209(21)00304-9. doi: 10.1016/j.clbc.2021.10.013. Online ahead of print.PMID: 34903452 Publication link.

 

帕博西尼辅助治疗早期乳腺癌:PALLAS试验结果(ABCSG-42/AFT-05/BIG-14-03)

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators. 帕博西尼辅助治疗早期乳腺癌:PALLAS试验结果(ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554. Online ahead of print.PMID: 34874182 Publication link.

基于铂的化疗与卡培他滨在新辅助化疗后残余三阴性乳腺癌患者中的随机III期术后试验:ECOG-ACRIN EA1131

Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. 基于铂的化疗与卡培他滨在新辅助化疗后残余三阴性乳腺癌患者中的随机III期术后试验:ECOG-ACRIN EA1131. J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976. Online ahead of print.PMID: 34092112 Publication link.

HER2异质性对早期HER2阳性乳腺癌治疗反应的影响:T-DM1联合帕妥珠单抗的II期新辅助临床试验

Metzger Filho O, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. HER2异质性对早期HER2阳性乳腺癌治疗反应的影响:T-DM1联合帕妥珠单抗的II期新辅助临床试验. Cancer Discov. 2021 May 3:candisc.1557.2020. doi: 10.1158/2159-8290.CD-20-1557. Online ahead of print.PMID: 33941592 Publication link.

pik3ca突变激素受体阳性患者报告的预后, 人表皮生长因子受体2阴性晚期乳腺癌来自SOLAR-1

Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, 人表皮生长因子受体2阴性晚期乳腺癌来自SOLAR-1. J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139. Online ahead of print.PMID: 33780274 Publication link.

PI3K抑制剂alpelisib联合nab-紫杉醇治疗her2阴性转移性乳腺癌的I/II期临床和生物标志物研究结果

Sharma P, Abramson VG, O'Dea AP, Nye L, Mayer IA, Pathak HB, Hoffmann M, Stecklein SR, Elia M, Lewis S, Scott J, De Jong JA, Wang YY, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson S, Phadnis MA, Reed GA, Kimler BF, Khan QJ, Godwin AK. PI3K抑制剂alpelisib联合nab-紫杉醇治疗her2阴性转移性乳腺癌的I/II期临床和生物标志物研究结果. Clin Cancer Res. 2021 Feb 18:clincanres.4879.2020. doi: 10.1158/1078-0432.CCR-20-4879. Online ahead of print.PMID: 33602685 Publication link.

三阴性乳腺癌患者全因死亡率的种族差异

Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO. 三阴性乳腺癌患者全因死亡率的种族差异. Cancer Res. 2020 Dec 3:canres.3094.2020. doi: 10.1158/0008-5472.CAN-20-3094. Online ahead of print.PMID: 33272926 Publication link.

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, 人类表皮生长因子受体2阴性晚期乳腺癌:SOLAR-1的最终总生存结果

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, 人类表皮生长因子受体2阴性晚期乳腺癌:SOLAR-1的最终总生存结果. Ann Oncol. 2020 Nov 24:S0923-7534(20)43166-7. doi: 10.1016/j.annonc.2020.11.011. Online ahead of print.PMID: 33246021. Publication link.

Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial

Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2020 Sep 28:djaa148. doi: 10.1093/jnci/djaa148. Online ahead of print.PMID: 32986828. Publication link.

Sacituzumab Govitecan治疗先前治疗的激素受体阳性/ her2阴性转移性乳腺癌:1/2期的最终结果, Single-Arm, Basket Trial

Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab Govitecan治疗先前治疗的激素受体阳性/ her2阴性转移性乳腺癌:1/2期的最终结果, Single-Arm, Basket Trial. Ann Oncol. 2020 Sep 15:S0923-7534(20)42445-7. doi: 10.1016/j.annonc.2020.09.004. Online ahead of print.PMID: 32946924. Publication link.

Veeva ID: Z4-40714
Date of preparation: December 2021